期刊文献+

辛伐他汀咀嚼片的人体药代动力学和相对生物用度 被引量:9

Pharmacokinetics and Relative Bioavailability of Simvastatin Chew Tablet in Healthy Volunteers after A Single Oral Administration
下载PDF
导出
摘要 目的:研究辛伐他汀咀嚼片在20名健康志愿者体内的药动学特征及相对生物利用度。方法:20名健康男性志愿者采用随机交叉给药方案,分别单剂量口服的40mg辛伐他汀咀嚼片和参比片,采用液-液相萃取后、HPLC-ESI-MS分析方法对血药浓度进行测定,计算两者的药代动力学参数及相对生物利用度。结果:试验片和参比片的血药浓度水平一致。其主要药代动力学参数t1/2分别为3.46±0.61和3.53±0.85h;tmax分别为1.2±0.5h和1.4±0.6h,Cmax分别为7.03±3.33μg·L-1和7.04±3.78μg·L-1,AUC0-14分别为23.22±9.96μg·h·L-1和23.57±9.41μg·h·L-1,两制剂的药代动力学参数相近。用面积估算的辛伐他汀咀嚼片的相对生物利用度F0-14为97.9%±11.1%,F0-∞为97.6%±11.4%。结论:辛伐他汀咀嚼片和参比片的AUC、Cmax经方差分析和双单侧t-检验表明:两制剂生物等效;tmax经非参数法检验,表明两种制剂无显著性差别(>0.05)。 OBJECTIVE:To study the pharmacokinetics and relative bioavailability of simvastatin in 20 healthy volunteers. METHODS:A single oral dose 40mg simvastatin of reference or test drugs was given to each volunteer according to an open randomized crossover study. The concentrations in plasma were determined by HPLC-ESI-MS method after liquid-liquid extraction methods. RESULT:The main pharmacokinetics parameters of simvastatin were as follows:t1/2 were 3.46±0.61 and 3.53 ± 0.85h, tmax were 1.2 ± 0.5h and 1.4 ± 0.6h,C were 7.03 ± 3.33 μ g·L-1 and 7.04 ± 3.78μ g·L-1, AUC0-14 were 23.22 ?9.96 μg·h-L-1 and 23.57 ±9.41 μ g·h·L-1for test and reference tablet respectively. The relative bioavailability of F0-14 and F0-∞ were 97.9% ± 11.1% and 97.6% ± 11.4% respectively. CONCLUSION:The result of statistical analysis showed that two formulations were bioequivalent.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2002年第6期441-444,共4页 The Chinese Journal of Clinical Pharmacology
关键词 咀嚼片 相对生物用度 辛伐他汀 药代动力学 液相色谱-质谱联用 液-液相萃取法 降血脂药 simvastatin pharmacokinetics LC-MS liquid-liquid extraction
  • 引文网络
  • 相关文献

参考文献7

  • 1俞进.降胆固醇新药──胆固醇合成抑制剂[J].首都医学院学报,1995,16(1):80-81. 被引量:7
  • 2Endo A, Kuroda M,Tsuhita Y. ML-236A, ML-236B, and ML236C, new inhibitors of cholesterogenesis produced by peniciuium citrinum, J Antibiot, 1976;29:1346~1348.
  • 3Hisao O, Naotaka U, Kazuhode I, et al. Determination of simvastatin and its active metabolite in human plasma by columnswitching high-performance liquid chromatography with fluorescence detection after derivatization with lbromoacetylpyrene. J Chromatogr B, 1997(694):211~217.
  • 4Endo A, Hasumi K, Tsuhita Y, Momacolins J, et al., new inhibitors of cholesterol biosynthesis produced by monascus rubber, J Antibiot,1985 ;38:420~422.
  • 5Kakano T, Abe S, Hata S.A selected ion monitoring method for quantifying simvastatin and its acid form inhuman plasma using the ferroceneboronate derivative. Biomed. Environ. Mass Spectrom,1990;19:577~581.
  • 6Morris MJ, Gilbert JD, Hiseh JYK. et, al. Determination of the HMG-CoA reductase inhibitors simastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Mass Spectr, 1993 ;22:1~8.
  • 7Mauro V F. Clinical pharmacokinetics and practical applications of simvatatin. Clin Pharmacokin, 1993;24:195~202.

共引文献6

同被引文献51

引证文献9

二级引证文献31

;
使用帮助 返回顶部